Physician profile
Robert Knight
NPI 1639258932
$12,019.26
in general payments reported to CMS, 2019-2025
57 companies · $1,845 in 2025
The $1,845 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,692 · 2020: $1,320 · 2021: $1,420 · 2022: $1,567 · 2023: $2,319 · 2024: $1,856 · 2025: $1,845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,020.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,586.10 | 2019-2025 | |
| Novo Nordisk INC | $1,437.04 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,327.40 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $985.37 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $838.21 | 2019-2025 | Evenity, Repatha, Otezla |
| Pfizer INC. | $772.66 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $431.22 | 2019-2025 | Spravato |
| Amarin Pharma, INC. | $381.83 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $366.78 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $313.72 | 2019-2025 | Verquvo, Gardasil 9, Belsomra |
| Glaxosmithkline, LLC. | $309.14 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $249.65 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lundbeck LLC | $246.85 | 2020-2025 | Rexulti |
| Astellas Pharma US INC | $240.69 | 2019-2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $222.36 | 2020-2025 | Rexulti |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Knight listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.